PDCD1 and melanoma: Also, there is a gradually increasing appreciation of the great discrepancy of response to the anti-PD-1 monotherapy between different melanoma subtypes, specifically acral and mucosal melanomas, which are predominant in Asian populations and have poorer responses compared with their cutaneous counterpart (24, 25) due to their distinct genomic and immunological makeups (22).